Quest Diagnostics Q2 revenue up 10.2% to $3.04 billion; raises 2026 guidance
Quest Diagnostics reported second-quarter 2026 net revenues of $3.04 billion, up 10.2% from a year earlier, and reported diluted EPS of $2.84, up 15.0%. The company raised its full-year 2026 revenue and EPS guidance, which matters to shareholders because it expects higher earnings for the year than it previously forecast.
Key points
- Q2 net revenues $3.04 billion, up 10.2%, with 10.0% organic revenue growth
- Q2 reported diluted EPS $2.84, up 15.0%; adjusted diluted EPS $3.12, up 19.1%
- Full-year 2026 revenue guidance raised to $11.95 billion to $12.05 billion from $11.78 billion to $11.90 billion
- Full-year adjusted diluted EPS guidance raised to $11.05 to $11.25 from $10.63 to $10.83; Q2 reported operating margin was 15.1% versus 15.9% a year earlier
The filing
Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 23, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.